Drug-resistant tumor progression, coupled with the development of lethal metastasis, are the commonest cause of cancer mortality. However, the lack of effective targeted therapy remains the greatest challenge in treating drug-refractory and metastatic cancers.
Nuclear hormone receptors are a family of DNA sequence-specific binding transcription factors that regulate tumorigenesis. Endocrine therapies that reduce hormone production and block hormone receptor function have significantly improved survival for patients with estrogen receptor-positive breast cancer and androgen receptor-positive prostate cancer. However, the success of standard-of-care is compromised by drug resistance and metastasis. Therefore, it is critical to study the biomarkers and mechanisms of drug response as well as the roles of other types of nuclear hormone receptors in cancer development and progression. This Research Topic deals with targeting nuclear hormone receptors and their signaling pathways to overcome drug resistance in cancer therapy.
In this Research Topic, we focus on the role of nuclear hormone receptors in treatment-refractory cancer and targeted therapy. Our goal is to investigate the mechanisms that nuclear hormone receptors drive tumor progression, drug resistance and/or metastasis and to identify new drug targets for potential treatment. We emphasize the discovery of nuclear hormone receptor-based therapeutic vulnerabilities in cancers to accelerate the application of precision therapeutics, thus improving clinical outcomes for cancer patients.
We welcome research articles, research reports, reviews, mini-reviews, and resource papers that are related but not limited to:
• New biological functions and mechanisms of nuclear hormone receptors in cancer
• Novel biomarkers of diagnosis, prognosis and drug response in hormone receptor-dependent cancers
• New techniques to detect the role of nuclear hormone receptors in therapeutic resistance and cancer
• Novel therapies to target nuclear hormone receptors and transcriptional machinery in cancer
• Pre-clinical and clinical studies
Drug-resistant tumor progression, coupled with the development of lethal metastasis, are the commonest cause of cancer mortality. However, the lack of effective targeted therapy remains the greatest challenge in treating drug-refractory and metastatic cancers.
Nuclear hormone receptors are a family of DNA sequence-specific binding transcription factors that regulate tumorigenesis. Endocrine therapies that reduce hormone production and block hormone receptor function have significantly improved survival for patients with estrogen receptor-positive breast cancer and androgen receptor-positive prostate cancer. However, the success of standard-of-care is compromised by drug resistance and metastasis. Therefore, it is critical to study the biomarkers and mechanisms of drug response as well as the roles of other types of nuclear hormone receptors in cancer development and progression. This Research Topic deals with targeting nuclear hormone receptors and their signaling pathways to overcome drug resistance in cancer therapy.
In this Research Topic, we focus on the role of nuclear hormone receptors in treatment-refractory cancer and targeted therapy. Our goal is to investigate the mechanisms that nuclear hormone receptors drive tumor progression, drug resistance and/or metastasis and to identify new drug targets for potential treatment. We emphasize the discovery of nuclear hormone receptor-based therapeutic vulnerabilities in cancers to accelerate the application of precision therapeutics, thus improving clinical outcomes for cancer patients.
We welcome research articles, research reports, reviews, mini-reviews, and resource papers that are related but not limited to:
• New biological functions and mechanisms of nuclear hormone receptors in cancer
• Novel biomarkers of diagnosis, prognosis and drug response in hormone receptor-dependent cancers
• New techniques to detect the role of nuclear hormone receptors in therapeutic resistance and cancer
• Novel therapies to target nuclear hormone receptors and transcriptional machinery in cancer
• Pre-clinical and clinical studies
